Unbuzzd Wellness Inc. Launches $5 Million Regulation D Offering to Fuel Growth and IPO Ambitions

Unbuzzd Wellness Inc., a portfolio company of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), has announced the launch of a Regulation D 506(c) offering aimed at raising up to $5 million. This strategic move is designed to fund the company's growth initiatives and advance its trajectory toward a potential initial public offering (IPO). Notably, this capital raise includes an anti-dilution provision that safeguards Quantum BioPharma's 25% ownership stake in Unbuzzd until the beverage company achieves a $1 billion valuation.

Unbuzzd is the creator of unbuzzd(TM), a innovative beverage formulated to accelerate alcohol metabolism, enhance mental clarity, and mitigate hangover symptoms. To facilitate this offering, Unbuzzd has partnered with MZ Digital and Dealmaker, enabling the campaign to accept both traditional and cryptocurrency investments. John Duffy, CEO of Unbuzzd, emphasized that the proceeds from this offering will be instrumental in expanding the company's direct-to-consumer, distributor, and retail channels. Gerry David, Co-Chair of the Board, highlighted the partnership as a critical step in positioning Unbuzzd for a future IPO.

Quantum BioPharma Ltd., the parent company, is a biopharmaceutical firm with a focus on developing innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse. Through its subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is advancing Lucid-MS, a patented compound aimed at addressing the underlying mechanisms of multiple sclerosis. The company's strategic investments, including its stake in Unbuzzd, underscore its commitment to fostering groundbreaking biotech and wellness solutions.

For more details on Quantum BioPharma and its portfolio, visit https://ibn.fm/QNTM. To learn more about Unbuzzd and its offerings, visit https://www.unbuzzd.com.